• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Abacavir/Dolutegravir/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient.阿巴卡韦/多替拉韦/拉米夫定（绥美凯）致人类免疫缺陷病毒感染患者肝毒性
Open Forum Infect Dis. 2017 Jun 12;4(3):ofx122. doi: 10.1093/ofid/ofx122. eCollection 2017 Summer.
2
Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.一名26岁男性故意过量服用多替拉韦/阿巴卡韦/拉米夫定（绥美凯）。
Antivir Ther. 2018;23(6):549-552. doi: 10.3851/IMP3229.
3
Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient.一名感染人类免疫缺陷病毒（HIV）的患者使用绥美凯（阿巴卡韦/多替拉韦/拉米夫定）后发生横纹肌溶解的病例报告。
Medicine (Baltimore). 2019 Apr;98(17):e15149. doi: 10.1097/MD.0000000000015149.
4
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.阿巴卡韦/多替拉韦/拉米夫定单片复方制剂：在人类免疫缺陷病毒 1 型感染中的应用评价。
Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6.
5
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.将绥美凯（Triumeq®）换成仿制药（阿巴卡韦+拉米夫定）+特威凯（Tivicay®）的疗效和安全性：24周数据
BMC Pharmacol Toxicol. 2018 Oct 10;19(1):63. doi: 10.1186/s40360-018-0252-z.
6
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1489）：一项双盲、多中心、3 期、随机、对照非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.
7
Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature.多替拉韦引起的肝损伤导致亚急性肝衰竭需进行肝移植：一例病例报告及文献综述
Int J STD AIDS. 2018 Mar;29(4):414-417. doi: 10.1177/0956462417734099. Epub 2017 Oct 23.
8
A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1.阿巴卡韦/多替拉韦/拉米夫定用于HIV-1患者的韩国上市后研究。
Infect Chemother. 2023 Sep;55(3):337-345. doi: 10.3947/ic.2022.0176. Epub 2023 May 4.
9
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.奥比他韦-帕利瑞韦-利托那韦联合达沙布韦的直接抗病毒治疗方案与HIV抗逆转录病毒药物多替拉韦或阿巴卡韦联合拉米夫定之间的药物相互作用。
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6244-51. doi: 10.1128/AAC.00795-16. Print 2016 Oct.
10
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.在肌萎缩侧索硬化症中使用 Triumeq 的安全性和耐受性：灯塔试验。
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):595-604. doi: 10.1080/21678421.2019.1632899. Epub 2019 Jul 8.

引用本文的文献

1
Supplementing HIV-ART with cannabinoids increases serotonin, BHB, and Ahr signaling while reducing secondary bile acids and acylcholines.用大麻素补充抗逆转录病毒疗法可增加血清素、β-羟基丁酸酯（BHB）和芳烃受体（Ahr）信号传导，同时减少次级胆汁酸和酰基胆碱。
Sci Adv. 2025 Sep 5;11(36):eadw4021. doi: 10.1126/sciadv.adw4021. Epub 2025 Sep 3.
2
Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.多替拉韦的上市后安全性问题：一项基于美国食品药品监督管理局不良事件报告系统数据库的药物警戒研究。
Front Pharmacol. 2025 Jul 30;16:1625601. doi: 10.3389/fphar.2025.1625601. eCollection 2025.
3
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.可分散片剂和速释阿巴卡韦/多替拉韦/拉米夫定片在HIV感染儿童中的疗效、安全性和耐受性：IMPAACT 2019第48周结果
Pediatr Infect Dis J. 2025 May 29;44(8):777-84. doi: 10.1097/INF.0000000000004859.
4
Liver function tests, CD4 counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study.与基于依非韦伦的抗逆转录病毒治疗相比，接受多替拉韦治疗的HIV感染者的肝功能检查、CD4细胞计数和病毒载量；一项比较性横断面研究。
Heliyon. 2024 Jun 14;10(12):e33054. doi: 10.1016/j.heliyon.2024.e33054. eCollection 2024 Jun 30.
5
Lam Leaf Extract Stimulates NRF2 and Attenuates ARV-Induced Toxicity in Human Liver Cells (HepG2).樟树叶提取物刺激NRF2并减轻抗逆转录病毒药物在人肝细胞（HepG2）中诱导的毒性。
Plants (Basel). 2023 Apr 3;12(7):1541. doi: 10.3390/plants12071541.
6
The Potential of to Ameliorate HAART-Induced Pathophysiological Complications.治疗 HIV 药物引起的病理生理学并发症的潜力。
Cells. 2022 Sep 24;11(19):2981. doi: 10.3390/cells11192981.
7
Dolutegravir in pregnancy-effects on HIV-positive women and their infants.多替拉韦在妊娠中的应用——对 HIV 阳性孕妇及其婴儿的影响。
Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):495-500. doi: 10.1007/s10096-018-3195-9. Epub 2018 Feb 2.

本文引用的文献

1
Abacavir-induced liver toxicity.阿巴卡韦所致肝毒性。
Braz J Infect Dis. 2016 Sep-Oct;20(5):502-4. doi: 10.1016/j.bjid.2016.03.002. Epub 2016 Apr 4.
2
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.多替拉韦：初治整合酶抑制剂患者的临床及实验室安全性
HIV Clin Trials. 2014 Sep-Oct;15(5):199-208. doi: 10.1310/hct1505-199.
3
Abacavir-induced liver toxicity in an HIV-infected patient.
AIDS. 2014 Feb 20;28(4):613. doi: 10.1097/QAD.0000000000000139.
4
Hepatoxicity of new antiretrovirals: a systematic review.新型抗逆转录病毒药物的肝毒性：系统评价。
Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):126-33. doi: 10.1016/j.clinre.2013.02.008. Epub 2013 Mar 21.
5
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.在初治 HIV-1 感染的成人中，每日一次多替拉韦与拉替拉韦的比较：SPRING-2 随机、双盲、非劣效性研究的 48 周结果。
Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.
6
Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.抗反转录病毒药物相关肝毒性的临床综合征及后果。
Hepatology. 2010 Sep;52(3):1143-55. doi: 10.1002/hep.23716.
7
Abacavir-induced hepatotoxicity: a report of two cases.
AIDS. 2008 Nov 30;22(18):2557-8. doi: 10.1097/QAD.0b013e32831c8af4.
8
Antiretroviral drugs and liver injury.抗逆转录病毒药物与肝损伤
AIDS. 2008 Jan 2;22(1):1-13. doi: 10.1097/QAD.0b013e3282f0e2fd.
9
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.

阿巴卡韦/多替拉韦/拉米夫定（绥美凯）致人类免疫缺陷病毒感染患者肝毒性

Abacavir/Dolutegravir/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient.

作者信息

Christensen Erin S, Jain Rupali, Roxby Alison C

机构信息

Department of Pharmacy Services, and.

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.

出版信息

Open Forum Infect Dis. 2017 Jun 12;4(3):ofx122. doi: 10.1093/ofid/ofx122. eCollection 2017 Summer.

DOI:10.1093/ofid/ofx122
PMID:28748198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5522577/
Abstract

Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus-infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.

摘要

在临床试验中尚未报告与三协唯（阿巴卡韦/拉米夫定/多替拉韦）相关的药物性肝损伤。我们报告了一例人类免疫缺陷病毒感染患者因接触三协唯而出现肝毒性的病例。临床医生应始终意识到使用这些药物会有发生急性和迟发性肝炎的风险。建议密切监测。